Crohn’s Disease Bulk Plasma
Crohn's Disease Bulk Plasma is collected by apheresis from IRB-consented donors using Acid-Citrate-Dextrose Formula A (ACDA) and tested negative for HIV, HBV and HCV. Single-donor high-volume lots give a consistent immune-mediated IBD matrix for immunoassay development, spike-recovery and linearity work, ASCA serology, plasma proteomics, and extracellular vesicle or cell-free DNA isolation. Donors can be stratified by disease activity, Montreal classification and treatment status.
Crohn’s Disease Bulk Plasma for Immune-Mediated Inflammatory Bowel Disease Research
Crohn’s Disease Bulk Plasma is collected from IRB-consented donors diagnosed with Crohn’s disease using apheresis with ACDA (Acid-Citrate-Dextrose Formula A) as the anticoagulant. Apheresis collection yields far more plasma per donor than a standard venous draw, which is what makes single-donor bulk lots practical for assay development, reagent qualification and screening campaigns that would otherwise consume many small aliquots. Crohn’s disease is an immune-mediated inflammatory bowel disease driven by a dysregulated mucosal immune response to the gut microbiota in genetically susceptible individuals, not by a classical autoantibody response.
Why High-Volume Crohn’s Disease Plasma
- Single-donor bulk volume removes lot-to-lot donor variability from long assay development campaigns, so a Crohn’s-positive control matrix can stay constant from feasibility through validation.
- Crohn’s inflammation runs through the IL-12/IL-23, Th1/Th17 and TNF axis. Large volumes support the repeated dilution series, spike-recovery and linearity work needed to qualify multiplex cytokine panels in a disease-state matrix.
- ACDA is a citrate-dextrose anticoagulant; citrate chelates calcium and preserves complement and coagulation-sensitive analytes that are consumed when blood is allowed to clot for serum.
- Anti-Saccharomyces cerevisiae antibodies (ASCA) are common in Crohn’s disease and are antibodies to a microbial antigen rather than autoantibodies. Bulk lots supply enough material to develop and validate ASCA and other IBD serology assays against a consistent positive matrix.
- High-volume plasma also supports depletion, fractionation and affinity enrichment workflows, and isolation of extracellular vesicles or cell-free DNA, all of which consume input volume quickly.
- Bulk lots are useful as disease-state reference and calibration material for therapeutic drug monitoring assays covering anti-TNF, anti-IL-23 and anti-integrin biologics.
Donor Stratification Available
- Disease activity, including clinical remission versus active flare, with Harvey-Bradshaw Index or CDAI where documented
- Montreal classification: age at diagnosis, disease location (ileal, colonic, ileocolonic, upper GI) and behaviour (non-stricturing, stricturing, penetrating)
- Serology and laboratory results where available, including ASCA status, CRP and faecal calprotectin
- Treatment status: biologic-naive, anti-TNF, anti-IL-12/23 or anti-IL-23, anti-integrin, JAK inhibitor, corticosteroid or immunomodulator
- Surgical and complication history, including prior resection and perianal fistulising disease
- Matched healthy controls available, as well as ulcerative colitis donors for IBD subtype comparison
Product Features
- High-volume plasma collected via apheresis
- Anticoagulated using ACDA (Acid-Citrate-Dextrose Formula A)
- Tested and confirmed negative for HIV, HBV, and HCV
- Available fresh, with custom volumes upon request; volumes reported per lot
- Single-donor lots for consistency across long assay campaigns
- IRB-approved informed consent and HIPAA-compliant handling
De-identified Donor Data
- Clinically confirmed diagnosis of Crohn’s disease
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Clinical history and medication data available
- Additional Crohn’s disease-specific metadata available on request
Applications
- Immunoassay development, spike-recovery and linearity work in a disease-state matrix
- Disease-state positive control and calibration material for kit qualification
- Cytokine and inflammatory mediator profiling across the TNF and IL-23/Th17 axes
- ASCA and IBD serology assay development
- Plasma proteomic and metabolomic discovery requiring large input volumes
- Extracellular vesicle and cell-free DNA isolation
- Depletion, fractionation and affinity enrichment workflows
- Therapeutic drug monitoring and anti-drug antibody assay development
Other Crohn’s Disease Specimen Types
- Crohn’s Disease Plasma
- Crohn’s Disease Serum
- Crohn’s Disease Whole Blood
- Crohn’s Disease PBMC
- Crohn’s Disease Leukopak
- Crohn’s Disease CD19+ B Cells
Compliance and Quality Assurance
- Screened negative for HIV, HBV, and HCV
- IRB-approved collection with 21 CFR Part 11-compliant consent
- Standardized apheresis collection and processing protocols
- HIPAA-compliant donor data protection
Ordering & Customization
Crohn’s Disease Bulk Plasma is available in standard or custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For documentation or international shipping, please contact us to confirm regional compliance. To browse other disease states in this specimen type, visit our human plasma page.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Bulk Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.